22 unknown, 19 recruiting, 15 completed, 8 not yet recruiting. 31 Phase 2, 17 Not applicable, 10 Phase 1, 6 Phase 3, 1 Early Phase 1.
Follow Hepatocellular Carcinoma Non-Resectable: new trials by email Literature Review of Hepatocellular Carcinoma Non-Resectable trials Research Report on Hepatocellular Carcinoma Non-Resectable
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs ACE723 - Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Metastatic | Phase 1 | Not yet recruiting | Acepodia Biotech, Inc. | 70 | 2026-11-01 | 2026-10-06 |
| Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma TheraSphere® Yttrium-90 microspheres, Health Related Quality of Life Questionnaires (HRQOL) - Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma | Not applicable | Not yet recruiting | University of California, San Francisco | 64 | 2026-10-01 | 2026-10-06 |
| Overcoming Immunotherapy Resistance in Hepatocellular Carcinoma External beam radiotherapy, transarterial radioembolization - Hepatocellular Carcinoma Non-Resectable | Not applicable | Not yet recruiting | Radboud University Medical Center | 16 | 2026-10-01 | 2026-10-26 |
| Adjuvant Stereotactic Body Radiation Therapy After Trans-arterial Chemoembolization in Hepatocellular Carcinoma TACE, SBRT - Hepatocellular Carcinoma Non-resectable | Not applicable | Recruiting | RWTH Aachen University | 30 | 2026-05-05 | 2026-05-11 |
| Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis Selective Internal Radiotherapy, Tremelimumab, Durvalumab - Hepatocellular Carcinoma Non-resectable | Phase 2 | Recruiting | Center Eugene Marquis | 80 | 2026-02-25 | 2026-05-05 |
| A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Unresectable Hepatocellular Carcinoma Locoregional Therapy (LRT) + Systemic Drug Therapy - Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable | Not yet recruiting | Ningbo Medical Center Lihuili Hospital | 300 | 2026-01-25 | 2026-01-26 | |
| Adebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy Adebrelimab + Apatinib - Hepatocellular Carcinoma Non-resectable | Phase 2 | Not yet recruiting | Song Peng | 47 | 2025-09-01 | 2025-09-25 |
| Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC Lenvatinib plus SIRT, Lenvatinib - Hepatocellular Carcinoma Non-resectable | Phase 2 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 78 | 2025-04-01 | 2025-04-29 |
| Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT LEN+SIN+DEB-TACE+HAIC, LEN+SIN+DEB-TACE - Hepatocellular Carcinoma Non-resectable | Phase 2 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 320 | 2025-04-01 | 2026-08-11 |
| Fecal Microbiota Transplantation in Reversing Drug Resistance in Unresectable HCC (TALENP004) Fecal Microbiota Transplantation - Hepatocellular Carcinoma Non-resectable | Not yet recruiting | Fujian Provincial Hospital | 15 | 2025-01-01 | 2024-10-16 | |
| Chemotherapy With the Ralox Regimen Combined With Anlotinib and Penpulimab for Unresectable Hepatocellular Carcinoma Intravenous chemotherapy with the Ralox regimen combined with Anlotinib and Penpulimab - Hepatocellular Carcinoma Non-Resectable | Early Phase 1 | Active not recruiting | Nanfang Hospital, Southern Medical University | 30 | 2025-01-01 | 2026-08-05 |
| A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma Magnesium Microspheres, cTACE - Hepatocellular Carcinoma Non-Resectable | Phase 3 | Not yet recruiting | InnoBM Pharmaceuticals Co., Ltd. | 228 | 2025-01-01 | 2025-01-16 |
| Y-90 SIRT for Unresectable HCC Larger Than 7cm SIRT - Hepatocellular Carcinoma Non-Resectable | Phase 2 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 33 | 2024-12-01 | 2025-01-28 |
| Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China Yttrium-90 (Y-90) resin microspheres - Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Non-Resectable | Enrolling by invitation | GrandPharma (China) Co., Ltd. | 100 | 2024-08-22 | 2024-12-05 | |
| Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003) TACE, Lenvatinib combination with Sintilimab sequential radiotherapy - Hepatocellular Carcinoma Non-resectable | Recruiting | Fujian Provincial Hospital | 28 | 2024-08-15 | 2024-08-20 | |
| Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT Len+DEB-TACE+HAIC, Len+DEB-TACE - Hepatocellular Carcinoma Non-resectable | Phase 3 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 178 | 2024-08-01 | 2025-01-29 |
| A Phase 2, Single Arm Study of Cabozantinib in Patients With Hepatocellular Carcinoma Who Have Received Prior Atezolizumab and Bevacizumab Cabozantinib - Hepatocellular Carcinoma Non-resectable | Phase 2 | Not yet recruiting | Chulalongkorn University | 40 | 2024-08-01 | 2024-08-02 |
| Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma Lenvatinib - Hepatocellular Carcinoma Non-resectable | Phase 1 / Phase 2 | Active not recruiting | Assistance Publique - Hôpitaux de Paris | 25 | 2024-07-10 | 2025-04-07 |
| DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC DEB-TACE+HAIC, DEB-TACE - Hepatocellular Carcinoma Non-resectable | Phase 2 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 130 | 2024-05-01 | 2025-02-20 |
| Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC Sin-Bev-SIRT - Hepatocellular Carcinoma Non-resectable | Phase 2 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 23 | 2024-05-01 | 2024-05-07 |
Showing 20 of 74. Sign in to see all of them.
Carcinoma, Hepatocellular (46) · Liver Neoplasms (7) · Liver Diseases (3) · Adenocarcinoma (1) · Carcinoma (1) · Cholangiocarcinoma (1) · Colorectal Neoplasms (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Disease (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1) · Simpson-Golabi-Behmel syndrome (1)
Adenocarcinoma (45) · Carcinoma (45) · Digestive System Diseases (45) · Digestive System Neoplasms (45) · Neoplasms (45) · Neoplasms by Histologic Type (45) · Neoplasms by Site (45) · Neoplasms, Glandular and Epithelial (45) · Liver Diseases (43) · Liver Neoplasms (39) · Colonic Diseases (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Intestinal Diseases (1) · Intestinal Neoplasms (1)
lenvatinib (11) · sintilimab (7) · Bevacizumab (6) · camrelizumab (6) · Sorafenib (5) · atezolizumab (5) · apatinib (4) · Immune Checkpoint Inhibitors (3) · donafenib (3) · regorafenib (3) · spartalizumab (3) · Fluorouracil (2) · Glutamyl Aminopeptidase (2) · Sirtuins (2) · cabozantinib (2)
Second Affiliated Hospital of Guangzhou Medical University (17) · Tianjin Medical University Cancer Institute and Hospital (3) · ABK Biomedical (2) · Center Eugene Marquis (2) · Fujian Provincial Hospital (2) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (2) · Jeil Pharmaceutical Co., Ltd. (2) · Tongji Hospital (2) · UMC Utrecht (2) · Abbott (1) · Acepodia Biotech, Inc. (1) · Asan Medical Center (1) · Assistance Publique - Hôpitaux de Paris (1) · Beijing 302 Hospital (1) · CbsBioscience (1)
China (43) · France (6) · Germany (6) · South Korea (6) · United States (6) · Netherlands (4) · Taiwan (4) · Hong Kong (3) · Italy (3) · Belgium (2) · Canada (2) · New Zealand (2) · Singapore (2) · Argentina (1) · Australia (1)
Kangshun Zhu, Dr. (5) · Arndt Vogel, Prof. Dr. (2) · Etienne Garin, MD PHD (2) · Kangshun Zhu, MD (2) · Salah-Eddin Al-Batran, Prof. Dr. (2) · Ahmed Allam Mohamed, MBBS, MSc, MD (1) · Ammar Sarwar, MD (1) · Andrew Kennedy, MD (1) · Aravind Arepally, MD (1) · Caide Lu, Professor (1) · Chien-Hung Chen, MD (1) · Gang Chen, MD,PhD (1) · Han Dr. Gao (1)
PMID 25488963, PMID 32112738, PMID 34052255, PMID 35081747, PMID 35101942, PMID 36852452, PMID 38291865, PMID 38869974, PMID 39786516, PMID 39972606, PMID 41293180, PMID 42682622
2019 (3), 2009 (1), R01CA262460 (1)